Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer

Clinical Cancer Research

Volumn 13, Issue 2 I, 2007, Pages 382-387

  Osaki, Tomohiro ^a   Saito, Hiroaki ^a   Yoshikawa, Toshiaki ^a   Matsumoto, Sachiko ^a   Tatebe, Shigeru ^a   Tsujitani, Shunichi ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICA ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; STOMACH NEOPLASMS; TIME FACTORS;

EID: 33846868891     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1454     Document Type: Article

References (24)

1. Ries L, Eisner M, Kosary C. SEER cancer statistics review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. p. 2003.
2. Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-5.
3. Hoshino T, Seki N, Kikuchi M, et al. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-8.
4. Glienke J, Sobanov Y, Brostjan C, et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics 1998;48:163-73.
5. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-90.
6. Watzl C. The NKG2D receptor and its ligands - recognition beyond the "missing self"? Microbes Infect 2003;5:31-7.
7. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002;14:306-11.
8. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
9. Cerwenka A, Bakker AB, McClanahan T, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-7.
10. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-26.
11. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
12. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001;98:11521-6.
13. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
14. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
15. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
16. Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003;171:6891-9.
17. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 13th ed. Tokyo: Kanehara; 1999.
19. Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCRζ molecules in patients with gastric cancer. Clin Cancer Res 2001;7:74-80.
20. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
21. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172:7335-40.
22. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005;106:1711-7.
23. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37
24. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006;7:755-62.